Shares of Verici Dx plc (LON:VRCI – Get Free Report) were down 2.5% during trading on Thursday . The company traded as low as GBX 6.58 ($0.09) and last traded at GBX 6.58 ($0.09). 323 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 336,867 shares. The stock had previously closed at GBX 6.75 ($0.09).
Verici Dx Stock Up 1.8 %
The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The stock has a market cap of £16.66 million, a P/E ratio of -343.50 and a beta of 1.59. The stock’s fifty day moving average price is GBX 6.95 and its 200 day moving average price is GBX 7.77.
Verici Dx Company Profile
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
See Also
- Five stocks we like better than Verici Dx
- 10 Best Airline Stocks to Buy
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- What Are Growth Stocks and Investing in Them
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- NYSE Stocks Give Investors a Variety of Quality Options
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
